Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet CagriSema vs. Tirzepatide: Which One MELTS Fat Faster? Dr. Dan Obesity Expert Efficacy and Safety of Tirzepatide for Weight Management in Non Diabetic Obese Individuals: A Narrative Review